☆ 4.7 Article

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

NEUROPSYCHOPHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants

Anna M. Becker et al.

Summary: This study aimed to investigate whether ketanserin can reverse the effects of LSD when administered after LSD. The results showed that ketanserin reversed the acute response to LSD, significantly reducing the duration of subjective effects. Ketanserin also reversed LSD-induced alterations of mind, reduced adverse cardiovascular effects and had no effects on elevations of brain-derived neurotrophic factor levels. Ketanserin did not alter the pharmacokinetics of LSD.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial

Robin von Rotz et al.

Summary: In this double-blind, randomized clinical trial, a single, moderate dose of psilocybin was found to significantly reduce depressive symptoms compared to a placebo condition for at least two weeks, with no serious adverse events recorded. Larger, multi-centric trials with longer follow-up periods are needed to further optimize this novel treatment paradigm.

ECLINICALMEDICINE (2023)

Add to Collection

Article Neurosciences

Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Friederike Holze et al.

Summary: This study investigated the efficacy and safety of LSD-assisted therapy in patients with anxiety, with or without a life-threatening illness. The results showed that LSD treatment led to significant reductions in anxiety and comorbid depression symptoms, with effects lasting up to 16 weeks.

BIOLOGICAL PSYCHIATRY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

Anna M. Becker et al.

Summary: The study examined the interaction between escitalopram and psilocybin in the treatment of depression and anxiety. Escitalopram pretreatment was found to reduce certain negative effects of psilocybin, but further research is needed to fully understand the interactions between antidepressants and psilocybin in patients with psychiatric disorders.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Clinical Neurology

The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects

Malin Vedoy Uthaug et al.

Summary: The study found that the majority of English-speaking adults use mescaline infrequently for spiritual exploration or to connect with nature, with low potential for abuse and positive effects on mental health. Most respondents reported improvements in their psychiatric conditions following their most memorable mescaline experience.

JOURNAL OF PSYCHOPHARMACOLOGY (2022)

Add to Collection

Article Neurosciences

Safety pharmacology of acute LSD administration in healthy subjects

Friederike Holze et al.

Summary: This study found that LSD has dose-dependent subjective, physiological, and adverse effects. Most subjects reported good drug effects at doses of 50 μg and above, but also experienced negative effects. The physiological effects of LSD were moderate, with no serious psychological or physical harm observed.

PSYCHOPHARMACOLOGY (2022)

Add to Collection

Article Neurosciences

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

Friederike Holze et al.

Summary: This study compared the subjective and autonomic effects of LSD and psilocybin, finding that the higher doses of both substances produced similar subjective effects, but psilocybin had weaker effects at a lower dose. Additionally, LSD and psilocybin showed differences in their effects on heart rate and blood pressure.

NEUROPSYCHOPHARMACOLOGY (2022)

Add to Collection

Article Chemistry, Analytical

Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma

Jan Thomann et al.

Summary: In this study, a bioanalytical method was developed for the rapid quantification of mescaline and its metabolites in human plasma. The method showed reliability and ease of use, making it suitable for forensic applications as well as investigating the clinical pharmacokinetics of mescaline.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2022)

Add to Collection

Article Neurosciences

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Friederike Holze et al.

Summary: This study evaluated the subjective and autonomic effects of different doses of LSD in healthy subjects. It found that LSD displayed dose-proportional pharmacokinetics and dose-dependently induced subjective responses, with a ceiling effect observed for good drug effects at 100 μg. The results suggest that future LSD research may benefit from dose finding based on these findings, and that the full psychedelic effects of LSD are primarily mediated by serotonin 5-HT2A receptor activation.

NEUROPSYCHOPHARMACOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders

Lea J. Mertens et al.

Summary: This review article outlines the potential therapeutic mechanisms of classical psychedelics in treating substance use disorders and depression. While results from modern clinical trials are promising, larger, blinded, randomized controlled trials are needed to ensure the clinical efficacy of psychedelics. Further research is necessary to understand the therapeutic mechanisms of classical psychedelics in modern psychiatry.

PHARMACOPSYCHIATRY (2021)

Add to Collection

Article Biochemical Research Methods

Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin ' s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma

Karolina E. Kolaczynska et al.

Summary: A rapid LC-MS/MS method was developed and validated for quantifying psilocin and its metabolite 4-HIAA in human plasma, showing good accuracy and precision over three validation runs. This method could assess the pharmacokinetics of psilocin and 4-HIAA and facilitate the clinical development of psilocybin.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)

Add to Collection

Article Medicine, General & Internal

Trial of Psilocybin versus Escitalopram for Depression

Robin Carhart-Harris et al.

Summary: The study compared the efficacy of psilocybin and escitalopram in treating patients with major depressive disorder. While there was no significant difference in antidepressant effects between the two drugs at week 6, secondary outcomes generally favored psilocybin over escitalopram, though these results were not adjusted for multiple comparisons. Larger and longer trials are needed to further compare psilocybin with established antidepressants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Psychiatry

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial

Alan K. Davis et al.

Summary: The study showed that psilocybin therapy with psychological support is effective in treating MDD, building on previous findings in patients with cancer and depression, as well as in a nonrandomized study in patients with treatment-resistant depression.

JAMA PSYCHIATRY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin

Friederike Holze et al.

Summary: The study found that LSD can enhance empathy with dose-dependent effects on emotional empathy and also increase plasma oxytocin levels, partially independent of the primary action on 5-HT2A receptors. These findings provide important implications for further research investigating the therapeutic effects of LSD in patients with empathy deficits and impairments in social functioning.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Psychiatry

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

Cato M. H. de Vos et al.

Summary: Clinical studies suggest that psychedelics induce rapid changes in neuroplasticity mechanisms, leading to alterations in gene and protein expression, increased neurotrophic factor levels, and enhanced dendritic complexity. Repeated administration of psychedelics can directly stimulate neurogenesis and elevate BDNF mRNA levels, indicating potential long-lasting effects on brain plasticity. Future research could focus on deciphering specific cellular mechanisms activated by different psychedelics to better understand their therapeutic potential.

FRONTIERS IN PSYCHIATRY (2021)

Add to Collection

Article Clinical Neurology

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Emmanuelle A. D. Schindler et al.

Summary: An exploratory study found that a single administration of psilocybin had a lasting therapeutic effect on migraine headaches, separate from its acute psychotropic effects. This highlights the importance of further investigating the clinical effects of select 5-HT2A receptor compounds in migraine and other neuropsychiatric conditions.

NEUROTHERAPEUTICS (2021)

Add to Collection

Article Neurosciences

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects

Friederike Holze et al.

NEUROPSYCHOPHARMACOLOGY (2020)

Add to Collection

Article Substance Abuse

Trends in LSD use among US adults: 2015-2018

R. Andrew Yockey et al.

DRUG AND ALCOHOL DEPENDENCE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects

Friederike Holze et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions

Ricardo Jorge Dinis-Oliveira et al.

CURRENT MOLECULAR PHARMACOLOGY (2019)

Add to Collection

Article Neurosciences

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences

Theresa M. Carbonaro et al.

PSYCHOPHARMACOLOGY (2018)

Add to Collection

Article Clinical Neurology

Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics

Dino Luethi et al.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)

Add to Collection

Review Psychiatry

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Albert Garcia-Romeu et al.

INTERNATIONAL REVIEW OF PSYCHIATRY (2018)

Add to Collection

Article Neurosciences

Alterations of consciousness and mystical-type experiences after acute LSD in humans

Matthias E. Liechti et al.

PSYCHOPHARMACOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation

Katrin H. Preller et al.

CURRENT BIOLOGY (2017)

Add to Collection

Article Clinical Neurology

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Anna Rickli et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Roland R. Griffiths et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Neurosciences

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Yasmin Schmid et al.

BIOLOGICAL PSYCHIATRY (2015)

Add to Collection

Article Clinical Neurology

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Frederick S. Barrett et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2015)

Add to Collection

Article Clinical Neurology

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Peter Gasser et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2015)

Add to Collection

Review Endocrinology & Metabolism

Prosocial effects of oxytocin and clinical evidence for its therapeutic potential

Nadine Striepens et al.

FRONTIERS IN NEUROENDOCRINOLOGY (2011)

Add to Collection

Article Neurosciences

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Roland R. Griffiths et al.

PSYCHOPHARMACOLOGY (2011)

Add to Collection

Article Emergency Medicine

Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)

C. M. Hysek et al.

EMERGENCY MEDICINE JOURNAL (2010)

Add to Collection

Article Multidisciplinary Sciences

Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)

Erich Studerus et al.

PLOS ONE (2010)

Add to Collection

Article Anthropology

Shamanism and San Pedro through Time: Some Notes on the Archaeology, History, and Continued Use of an Entheogen in Northern Peru

Bonnie Glass-Coffin

ANTHROPOLOGY OF CONSCIOUSNESS (2010)

Add to Collection

Article Cell Biology

Novel, unifying mechanism for mescaline in the central nervous system Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships

Peter Kovacic et al.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2009)

Add to Collection

Article Neurosciences

Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose

Tomas Palenicek et al.

PSYCHOPHARMACOLOGY (2008)

Add to Collection

Article Neurosciences

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

R. R. Griffiths et al.

PSYCHOPHARMACOLOGY (2006)

Add to Collection

Letter Medicine, General & Internal

Mescaline use for 5700 years

JG Bruhn et al.

LANCET (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.